Plantpraxis Biotecnologia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Plantpraxis biotecnologia. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Plantpraxis Biotecnologia Today - Breaking & Trending Today

PlantForm signs agreement with Bio-Manguinhos/Fiocruz to develop a biosimilar pembrolizumab cancer drug


Share this article
Share this article
GUELPH, ON, and RIO DE JANEIRO, Brazil, April 6, 2021 /PRNewswire/ - PlantForm Corporation, PlantPraxis Biotecnologia and Bio-Manguinhos/Fiocruz (Health Ministry of Brazil) today announced a collaborative research and development agreement to develop a biosimilar pembrolizumab for the Brazilian market.
The original antibody drug, pembrolizumab, is widely used in immunotherapy to treat a variety of cancers including melanoma, lung cancer, head and neck cancer, and stomach cancer.
This agreement advances PlantForm s collaborations in Brazil to make affordable, effective cancer drugs available to millions of Brazilians, said Dr. Don Stewart, PlantForm s President and CEO. It also advances PlantForm s global strategy for biosimilar drug development and manufacturing to increase affordability and access to a wide range of life-saving medications. ....

United States , Bio Manguinhos Fiocruz , Germana Regazzi , Don Stewart , Sotiris Missailidis , Plantpraxis Biotecnologia , Partnerships For Productive Development Pdps , Brazilian Ministry Of Health , Plantform Corp , Technological Development Of Bio Manguinhos Fiocruz , Bio Manguinhos Fiocruz Health Ministry Of Brazil , Plantform Corporation , Oswaldo Cruz Foundation Bio Manguinhos Fiocruz , History Of Public Health , Institute Of Technology On Immunobiologicals , Brazilian Universal Health System , Form Corporation , Health Ministry , Deputy Director , Technological Development , Axis Biotec Brazil , Brazilian Ministry , Oswaldo Cruz Foundation , Latin America , Public Health , Productive Development ,